Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,863 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Age is not a contraindication to pancreaticoduodenectomy.
Hodul P, Tansey J, Golts E, Oh D, Pickleman J, Aranha GV. Hodul P, et al. Among authors: oh d. Am Surg. 2001 Mar;67(3):270-5; discussion 275-6. doi: 10.1016/s0016-5085(00)81967-8. Am Surg. 2001. PMID: 11270888
Current concepts in chronic venous ulceration.
Tassiopoulos AK, Golts E, Oh DS, Labropoulos N. Tassiopoulos AK, et al. Among authors: oh ds. Eur J Vasc Endovasc Surg. 2000 Sep;20(3):227-32. doi: 10.1053/ejvs.2000.1157. Eur J Vasc Endovasc Surg. 2000. PMID: 10986019 Free article. Review.
Viscoelastic properties of normal and atherosclerotic carotid arteries.
Labropoulos N, Ashraf Mansour M, Kang SS, Oh DS, Buckman J, Baker WH. Labropoulos N, et al. Among authors: oh ds. Eur J Vasc Endovasc Surg. 2000 Mar;19(3):221-5. doi: 10.1053/ejvs.1999.1008. Eur J Vasc Endovasc Surg. 2000. PMID: 10753683 Free article.
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, Anderson I, Curigliano G, de Miguel M, Kalra M, Oh DY, Park JO, Postel-Vinay S, Rha SY, Satoh T, Spanggaard I, Michelini F, Smith A, Machado KK, Saura C; DESTINY-PanTumor01 study group. Li BT, et al. Among authors: oh dy. Lancet Oncol. 2024 May 3:S1470-2045(24)00140-2. doi: 10.1016/S1470-2045(24)00140-2. Online ahead of print. Lancet Oncol. 2024. PMID: 38710187
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, Blanc JF, Li J, Bachini M, Żotkiewicz M, Abraham J, Patel N, Wang J, Ali M, Rokutanda N, Cohen G, Oh DY. Burris HA 3rd, et al. Among authors: oh dy. Lancet Oncol. 2024 May;25(5):626-635. doi: 10.1016/S1470-2045(24)00082-2. Lancet Oncol. 2024. PMID: 38697156 Clinical Trial.
3,863 results